Allterum Therapeutics

Allterum is initially focusing on developing therapies for patients with relapsed disease who may not have effective standard options available to them. In particular, patients with relapsed/refractory T-cell ALL and B-cell hematologic malignancies, while relatively rare, have a relatively poor prognosis as a result of a lack of effective therapies.